XENLETA has a
low propensity of resistance
due to its novel MOA1

Low propensity for resistance

Low propensity for resistance

due to unique ribosomal binding
via multiple interactions1

Novel mechanism of action (MOA)

Novel mechanism of action (MOA)

as a pleuromutilin with a chemical structure distinct
from existing classes of antibiotics used in CABP1

XENLETA is different from older antibiotics

It may remain active against isolates

that are resistant to: β-lactams, macrolides, quinolones,
tetracyclines, and other antibiotics1